f Objectives: The primary objective of this study was to characterize the pharmacokinetics of etonogestrel (ENG) released from a contraceptive implant in Ugandan women living with HIV who were receiving efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART), compared with ART-naive women over 24 weeks.
Introduction
Family planning services, including hormonal contraception, are essential to improving women's reproductive health. Each year, effective contraception prevents 188 million unintended pregnancies, thereby averting 1.1 million newborn and 150 000 maternal deaths, as well as 112 million abortions worldwide [1, 2] . Absence of effective contraception carries even greater risk for the over 16 million women living with HIV worldwide, in whom prevention of unintended pregnancy through use of effective contraception is a successful and cost-effective strategy to decrease the rate of perinatal HIV transmission [3, 4] . Progestin-only contraceptive implants are highly effective, with less than 1% failure rate over 12 months in a pooled survey of 43 countries [5] . Recently, contraceptive implants are increasingly used in sub-Saharan Africa with high rates of acceptability and there were an estimated 21 million implant users in Africa by the end of 2015 [6] . Two forms of contraceptive implants are available, the etonogestrel (ENG) implant, approved for 3 years of use, and the levonorgestrel (LNG) implant, approved for 5 years of use.
Despite clear benefits of hormonal contraception, significant drug-drug interactions with some antiretroviral medications create a critical barrier to successful contraceptive use in women living with HIV. The progestin hormone concentration released from the implant is low relative to other systemic hormonal contraceptive methods, making this method particularly vulnerable to contraceptive failure because of drug-drug interactions. Hormonal contraceptives are primarily metabolized by the cytochrome P450 (CYP) enzyme system, and some nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz (EFV) and nevirapine (NVP), are CYP inducers [7, 8] . NVP and EFV are widely prescribed in sub-Saharan Africa, and EFV-based antiretroviral therapy (ART) is, currently, the preferred first-line treatment regimen recommended by the WHO for adults living with HIV, including women of reproductive age [10] . In addition, international guidelines recommend that all adults living with HIV should be treated with ART regardless of CD4 þ cell count, thus approximately 13 million women living with HIV in Sub-Saharan Africa are candidates for EFV-based ART [9] .
Of concern, several pharmacokinetic studies of hormonal contraceptives have demonstrated a significant decrease in LNG and ENG exposure, after either oral or subdermal administration, when combined with EFV compared with when used alone, including LNG emergency contraception [10] , desogestrel combined oral contraceptive pill [11] , and ENG and LNG implants [12, 13] . Vieira et al. [12] reported when the ENG implant was used with EFV-based ART, the ENG median minimum concentration over 24 weeks was 61.9 pg/ml, which is below the reported ovulation suppression threshold for ENG of 90 pg/ml [14] . These pharmacokinetic data are supported by an additional six case reports of ENG implant contraceptive failures with combined EFVuse [15] [16] [17] [18] , as well as three recent clinical studies that reported pregnancy rates of 5.5-15% in women using LNG contraceptive implants while taking EFV-based ART [13, 19, 20] . A large retrospective cohort reported a pregnancy rate of 3.0/100 woman-years [95% confidence interval (CI) 1.4-4.7] among women using EFV-based ART with the ENG implant [19] . These findings are in stark contrast to the less than 1% pregnancy rate reported in women using the contraceptive implant without a coadministered interacting drug [5, 21] .
The primary aim of this study was to estimate the effect of EFV or NVP-based ART on the pharmacokinetics of ENG released from a subdermal contraceptive implant in women living with HIV over 24 weeks of combined use. Our secondary objective was to characterize the pharmacokinetics of EFV and NVP pre versus postinsertion of the ENG implant.
Methods
We conducted a nonrandomized, open-label, parallel group, pharmacokinetic study of Ugandan women living with HIV. All study procedures occurred at the Infectious Disease Institute (IDI) in Kampala, Uganda and were approved by the University of Pittsburgh (PRO14010195), the Joint Clinical Research Centre, and Uganda National Council of Science and Technology (HS 1618). This study followed the Declaration of Helsinki and was registered at clinicaltrials.gov (NCT02082652).
Participants
Family planning services are integrated into HIV care at IDI, thus all women receiving care at IDI receive comprehensive contraceptive counseling. Women at least 18 years of age who desired the contraceptive implant were offered study participation and informed consent was obtained before the initiation of screening procedures. Women were included if they were: not yet taking ART (ART-naive group), receiving NVP-based ART (NVP group; NVP 200 mg twice daily and two nucleoside reverse transcriptase inhibitors), or receiving EFV-based ART (EFV group; EFV 600 mg once daily and two nucleoside reverse transcriptase inhibitors). Participants in the ART groups were on stable ART for at least 1-month prior to enrollment. Participants using EFV-based ART were additionally required to use a copper intrauterine device (IUD) to minimize the risk of unintended pregnancy, because of accumulating data of observed pregnancies in women receiving contraceptive implants and EFV-based ART that was not observed with NVP-based ART [13, 20] . The IUD was placed by a trained member of the study team according to the WHO Medical Eligibility Criteria for contraceptive use [22] .
We excluded participants from the study if they had plasma HIV RNA greater than 400 copies/ml (ART groups only); had laboratory evidence of anemia (hemoglobin less than 9.0 gm/dl), liver disease (serum alanine transaminase above five times the upper limit of normal), or renal disease (serum creatinine above 2.5 times the upper limit of normal); or if they were currently pregnant or less than 30-days postpartum. Participants were also excluded if they were taking a medication contraindicated for use with ENG, EFV (EFV group only), or NVP (NVP group only); other medications with CYP-inducing (e.g. rifampin) or inhibiting (e.g. ritonavir) potential; or other hormonal contraceptive medications [21, 23] .
Study procedures
Within 30 days of screening, participants who met the study eligibility criteria returned for the enrollment visit. After a negative pregnancy test, a trained study team member placed an ENG implant (Implanon 68 mg) subdermally in the upper inner arm [21] . The most recent CD4 þ cell count was abstracted from the participant's medical record. Study visits occurred 1, 4, 12, and 24 weeks after implant placement. During each visit, staff assessed adverse events, updated a record of concomitant medications, and performed a urine pregnancy test. Participants were asked about implant-associated sideeffects using a structured questionnaire. Adherence to ART was assessed at each visit by participant report. Condom use was encouraged for all study groups at every visit to provide a second form of nonhormonal contraception and to prevent HIV transmission. At the completion of the study, participants could choose to keep the ENG implant and/or the IUD (as applicable), or have them removed by a study clinician.
Pharmacokinetic assessment
We collected blood samples to analyze ENG concentration at weeks 1, 4, 12, and 24 after ENG implant placement. For participants on ART, a single, timed blood sample was collected to analyze the NNRTI concentration at the screening and enrollment visits (two samples prior to implant placement were collected in each participant), then at 4, 12, and 24-weeks postimplant insertion. For participants on NVP-based ART, the pharmacokinetic sampling was performed 11-13 h after taking their last NVP dose. For participants on EFV-based ART, blood sampling was performed 12-14 h after their last EFV dose. For each sample, whole blood was collected into vacutainers (Becton Dickinson, Plymouth, UK) containing ethylenediaminetetraacetic acid anticoagulant. Samples were transported by a dedicated laboratory runner from the Private Ward in Mulago Hospital to the Makerere University-Johns Hopkins University Core Laboratory, where they were centrifuged at 3000 revolutions/min for 10 min to separate plasma within 1 h of collection. Plasma aliquots were stored at À70 8 C until they were analyzed.
ENG plasma samples were shipped on dry ice to the University of Pittsburgh small molecule biomarker core laboratory. ENG levels were quantitated using a modified method of HPLC linked to mass spectrometry [24] . The assay was validated over the calibration range of 25-1000 pg/ml. The interday relative SD were 12.4% for the 35 pg/ml quality control, 6.5% for the 175 pg/ml quality control, and 4.2% for the 875 pg/ml quality control. Antiretroviral plasma concentrations were analyzed at the Infectious Diseases Institute Translational Laboratory, Makerere University, using previously described HPLC methods with ultraviolet detection [25, 26] . The EFV assay was validated over a calibration range of 0.2-10 mg/l. The EFV interday precision was between 2.82 and 5.25%; accuracy was between 93.6 and 107%. The NVP assay was validated over a calibration range of 0.05-16.1 mg/l. The interday NVP precision was between 1.15 and 4.64%; accuracy was between 94.3 and 108.4%. The laboratory participates in an external quality assurance program for antiretroviral assays: Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie, the Netherlands (http://kkgt.nl/). All pharmacokinetic assays were validated in accordance with guidance from the US Food and Drug Administration [27] .
Statistical analysis
A sample size of 20 participants/group provided 80% power to detect a 35% change (1 SD) between groups in the ENG concentration at week 24, using an a level of 0.05, and allowed for up to 20% participant attrition (leaving at least 16 participants/group). This calculation considers a previously reported ENG mean concentration of 297.5 pg/ml (SD 104.5 pg/ml) with reported interpatient variability of 35%, from 15 women at 6-months postimplant insertion [28] .
The ENG geometric mean concentration with 90% CI was summarized by study visit and compared between the ART-naive group and each ART group as a geometric mean ratio (GMR) with 90% CI. Each participant's ENG area under the concentration-time curve area under curve (AUC) from weeks 0 to 24 (AUC 0-24 ) was determined using the trapezoidal rule (Phoenix WinNonlin; Certara, Princeton, New Jersey, USA). To evaluate the impact of ENG on the NNRTI concentration, the EFV or NVP geometric mean concentration was compared pre (at screening) to post (at week 24) implant insertion as a GMR with 90% CI. NNRTI and ENG concentrations were considered bioequivalent if the 90% CI of the GMR fell between 0.8 and 1.25 in accordance to guidance by the Food and Drug Administration [27] . All safety and adverse event data were characterized using the division of aids severity tables [29] , descriptively summarized and compared using the Kruskal-Wallis or Wilcoxon rank sum tests for continuous data, and a x 2 test for discrete data. All statistical analyses were conducted using IBM SPSS Statistics (IBM, Armonk, New York, USA).
Results

Demographic characteristics
Between September 2014 and July 2015, 64 participants were screened for the study. Four participants were excluded; three participants for detectable HIV RNA (>400 copies/mL) while taking EFV or NVP-based ART, and one participant for unprotected intercourse within two weeks prior to enrollment. Of the 60 participants enrolled, all completed the primary endpoint at week 24; however, one participant was excluded from the NVP group (missing sample) and one participant was excluded from the EFV group (ART nonadherence), leaving 58 participants eligible for the primary analysis (Fig. 1) . Overall, the median age of the study population was 29 years [interquartile range (IQR): [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , and 62% of the participants were married with a median parity of 3 (IQR: 2-4). Overall, the median weight and BMI was 57.8 kg (IQR: 51.3-67.8) and 23.0 kg/m 2 (IQR: 20.8-26.7), respectively. The ART-naive group had a higher median body weight than EFV group (P ¼ 0.045). The demographic characteristics of the study population by group are summarized in Table 1 .
Etonogestrel pharmacokinetics ENG pharmacokinetic data are summarized in Table 2 and Fig. 2 The number of participants in the EFV group with ENG concentrations below 90 pg/ml (reported threshold for ovulation suppression [14] ) was 9 (47%), 16 (84%), and 18 (95%) at weeks 4, 12, and 24, respectively. In contrast, all participants in the ART-naive and NVP groups had ENG concentrations above 90 pg/ml throughout the 6-month study duration.
Antiretroviral pharmacokinetics
NVP and EFV geometric mean concentrations measured throughout the study are summarized in Table 3 Despite this decrease in EFV concentrations, there were no participants in the EFV group with plasma EFV concentrations less than 1 mg/l, the proposed minimum threshold for mid-dosing interval EFV concentrations [30] .
Adverse events
There were 298 reported adverse events, 297 were mild intensity (grade 1) and one of moderate intensity (grade 2). The one adverse event of moderate intensity was because of menorrhagia in the NVP group. The cumulative adverse events that were possibly related to the ENG implant are summarized in the supplemental table, http://links.lww.com/QAD/B136. None of the participants discontinued study participation or implant use because of an adverse event.
Discussion
In this study, we found that women living with HIV who were using the ENG contraceptive implant in combination with EFV-based ART had 82% lower ENG plasma concentrations at week 24 compared with ART-naive women. Importantly, the reported ENG concentration threshold for ovulation suppression is 90 pg/ml [14] , and we observed geometric mean ENG concentrations below this threshold by week 4. These results suggest that the combined use of EFV-based ART and the ENG implant could decrease contraceptive efficacy of the implant as early as 1 month after implant placement in women taking concomitant EFV-based ART. Our findings are similar to a Brazilian study by Vieira et al. [12] who noted 63.4% lower serum ENG AUC over 24 weeks for women using the ENG implant with EFV compared to those not on ART. These findings are also similar to the Ugandan study of the LNG implant, which found 47% lower LNG concentrations for women on EFV-based ART when compared with those that were ART naive [13] .
In contrast, NVP-based ART did not affect the ENG exposure from the implant at weeks 12 and 24 after implant placement. We noted a decrease in the ENG concentrations at 1 and 4 weeks after implant placement (21 and 10%, respectively) when comparing the ARTnaive group to the NVP group; however, this small magnitude of change, so early in the product life when concentrations are highest, is not likely to have a clinically meaningful effect on the contraceptive efficacy. This study provides reassurance that the ENG implant may be safely combined with NVP-based ART regimens. These findings are also similar to those reported with the LNG implant in Ugandan women; LNG plasma concentrations at week 24 were similar for women on NVP-based ART compared with ART-naive women [13] . Despite this encouraging finding, NVP-based ART is no longer a preferred first-line ART strategy because of an increased risk of serious and potentially fatal hypersensitivity reactions and decreased efficacy when compared with EFV [31]. Unfortunately, many women living with HIV must choose between a more effective and better tolerated EFV-based ART regimen and an effective and highly desired implantable contraceptive method.
ENG is primarily metabolized by the CYP3A4 enzyme [32] , and both EFV and NVP are CYP3A4 inducers [8, 32] . Therefore, the decreased ENG exposure observed with concomitant EFV-based ARTuse is likely because of CYP3A4 enzyme induction and thus increased metabolism of ENG. Interestingly, NVP is also a CYP3A4 inducer, and it remains unclear why a similar effect is not observed with concomitant NVP-based ART and either ENG or LNG-based contraceptive implants [32] . It is possible that EFV is a more potent CYP3A4 inducer than NVP. Alternatively, other complex drug metabolic or drug transport pathways for ENG and LNG could be responsible for the interaction observed with EFV, yet not with NVP. Our study is limited by not evaluating ENG metabolites that perhaps could clarify the mechanism for this interaction, such as any additional role of glucuronidation. These mechanisms have yet to be fully elucidated, and indicate a knowledge gap in steroid contraceptive metabolism.
We observed a greater reduction in ENG in our Ugandan population as compared with a Brazilian population [12] (84 versus 63% reduction in AUC over 24 weeks, respectively). This result may be because of interindividual variability among two small pharmacokinetic studies (n ¼ 20 and 15/group, respectively), analytic differences between detecting ENG in the plasma versus serum, variation in drug disposition between study populations, or body weight differences. Higher body weight has been associated with decreased ENG exposure [33] , and the ART-naive group had a higher median body weight than the EFV group in our study. However, the lower body weight noted in the EFV group relative to the ART-naive group would imply that our estimates for impact of EFV on ENG exposure are conservative. With regard to genetic variations between study populations, Neary et al. [34] recently identified that Ugandan women expressing pharmacogenetic variations in CYP2B6 resulting in slow metabolism of EFV, and therefore higher overall EFV exposure, had lower LNG exposure when LNGsubdermal implant use was combined with EFV-based ART compared with Ugandan women without pharmacogenetic CYP2B6 variations. Given that polymorphisms influencing CYP2B6 are more common in some African populations, these women may be at greater risk of drug-drug interactions that jeopardize the contraceptive effectiveness of LNG and ENG implants with concomitant EFV use. Future evaluations are needed to confirm the influence of pharmacogenetic diversity on both LNG and ENG disposition.
Our study was a pharmacokinetic evaluation and did not include pharmacodynamic biomarkers of contraceptive efficacy such as inhibition of ovulation or cervical mucus thickening; thus, the clinical correlation between contraceptive efficacy and these pharmacokinetic observations cannot be confirmed. The participants in the EFV group had a copper IUD in place during the study to avoid unintended pregnancies. However, blood progestin concentrations have commonly been used as a marker for contraceptive efficacy for implantable and other hormonal contraceptives. For example, three pregnancies were reported in a total of 20 study participants on EFVbased ART while using the LNG implant and these pregnancies were associated with low plasma LNG concentrations [13] . In addition, retrospective analyses confirm that contraceptive failures are more frequent in women receiving EFV-based ART in combination with contraceptive implants [19, 20, 35] . Thus, decreased ENG exposure in the setting of concomitant EFV-based ART reported here is concerning for increased risk of contraceptive failures.
We also found a decrease in EFV exposure when comparing EFV concentrations measured prior to implant insertion to those at 24 weeks after ENG implant insertion. Notably, three participants had significant decreases in EFV concentrations over the study duration, and six others had modest decreases in EFV concentrations of at least 1 mg/l from screening to week 24 postimplant placement. None of the participants in the EFV group ever had EFV concentrations less than 1 mg/l, which is the proposed mid-dosing interval concentration related to antiretroviral effectiveness [30] . This indicates that the decrease in EFV concentration is likely not clinically significant. The reason for this finding is unclear. Lower EFV concentrations at 24-weeks postimplant insertion could be because of nonadherence, incorrect timing of drug doses, or a drug-drug interaction. One other study found statistically lower EFV concentrations when given with an oral contraceptive pill containing ethinyl estradiol/desogestrel (EFV concentrations: 3.3 versus 2.7 mg/l; P ¼ 0.03) [36] . However, Cohn et al. [37] showed no change in EFV exposure before depot medroxyprogesterone acetate injection compared with 4 or 12 weeks after injection. Scarsi et al. [13] reported that there was no change in either EFV or NVP concentrations before and after LNG implant insertion. Unfortunately, we do not have HIV viral load data at week 24 after implant insertion to more fully evaluate the clinical significance of this decline in EFV concentration following insertion of the ENG implant. Though our study relied on self-reported adherence to ART, the measured EFV and NVP concentrations from participants reflect recent adherence to these antiretrovirals, although we cannot confirm perfect ART adherence over the entire study duration. Notably, ART nonadherence may result in underestimation of the effect of EFV or NVP on ENG.
In summary, we present a pharmacokinetic evaluation of the subdermal ENG implant used concomitantly with two first-line ART regimens commonly used in SubSaharan Africa. Our study of Ugandan women is of critical public health importance to women in SubSaharan Africa who are at greatest risk for living with HIV, as well as for pregnancy-related mortality or complications. Contraceptive implants represent a highly desirable method of contraception because of their high efficacy and tolerability; thus, their combined use with EFV-based ART is expected to increase in Sub-Saharan Africa. Of grave concern is the consistency of these and other similar published pharmacokinetic results, combined with the published clinical findings of increased contraceptive failures in women using EFV-based ART and contraceptive implants. Future studies are urgently needed and should explore alternate strategies for provision of safe, effective implantable contraception for women on EFV-based ART.
